Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Cash & Equivalents (2016 - 2025)

Arcadia Biosciences filings provide 12 years of Cash & Equivalents readings, the most recent being $300000.0 for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 92.93% to $300000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $300000.0, a 92.93% decrease, with the full-year FY2025 number at $300000.0, down 92.93% from a year prior.
  • Cash & Equivalents hit $300000.0 in Q4 2025 for Arcadia Biosciences, down from $1.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $44.0 million in Q2 2021 to a low of $300000.0 in Q4 2025.
  • Median Cash & Equivalents over the past 5 years was $12.1 million (2023), compared with a mean of $15.3 million.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 340.55% in 2021 and later tumbled 92.93% in 2025.
  • Arcadia Biosciences' Cash & Equivalents stood at $28.7 million in 2021, then fell by 28.03% to $20.6 million in 2022, then crashed by 68.43% to $6.5 million in 2023, then crashed by 34.92% to $4.2 million in 2024, then tumbled by 92.93% to $300000.0 in 2025.
  • The last three reported values for Cash & Equivalents were $300000.0 (Q4 2025), $1.1 million (Q3 2025), and $1.4 million (Q2 2025) per Business Quant data.